(Q38245875)

31 August 2017

Guidance on the management of diarrhoea during cancer chemotherapy (English)

1 reference

31 August 2017

0 references

1 reference

Jervoise Andreyev

1

1 reference

31 August 2017

Paul Ross

2

1 reference

31 August 2017

Clare Donnellan

3

1 reference

31 August 2017

Elaine Lennan

4

1 reference

31 August 2017

Pauline Leonard

5

1 reference

31 August 2017

Caroline Waters

6

1 reference

31 August 2017

Linda Wedlake

7

1 reference

31 August 2017

John Bridgewater

8

1 reference

31 August 2017

Rob Glynne-Jones

9

1 reference

31 August 2017

William Allum

10

1 reference

31 August 2017

Ian Chau

11

1 reference

31 August 2017

Richard Wilson

12

1 reference

31 August 2017

David Ferry

13

1 reference

31 August 2017

1 September 2014

1 reference

Lancet Oncology Commission

31 August 2017

1 reference

31 August 2017

15

1 reference

31 August 2017

e447-60

1 reference

31 August 2017

10

1 reference

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

31 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Chemotherapy induced diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Predicting fluorouracil toxicity: can we finally do it?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

The protein kinase complement of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Mechanisms of TKI-induced diarrhea in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Predicting late effects of pelvic radiotherapy: is there a better approach?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Systematic review of agents for the management of gastrointestinal mucositis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Ipilimumab-induced acute severe colitis treated by infliximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Management of intestinal complications in patients with pelvic radiation disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A physiological approach to modernize the management of cancer chemotherapy-induced gastrointestinal toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Chemotherapy-induced lactose intolerance in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Small bowel function in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A systematic review of diagnostic tests for small intestinal bacterial overgrowth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Small intestinal bacterial overgrowth in patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Gastrointestinal and nutritional sequelae of bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Chemotherapy dose reductions in obese patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Exploring a link between fatigue and intestinal injury during pelvic radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Guidelines for the investigation of chronic diarrhoea, 2nd edition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Early goal-directed therapy in the treatment of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Increased drug delivery to the brain by P-glycoprotein inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Inhibition of postprandial pancreatic and biliary secretion by loperamide in patients with short bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A patient with jejunostomy liberated from home intravenous therapy after 14 years; contribution of balance studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Effects of short-time somatostatin infusion on the gastric and intestinal propulsion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970006-3

7 January 2021

10.1016/S1470-2045(14)70006-3

Identifiers

DOI

1 reference

31 August 2017

1 reference